Deutetrabenazine
Brand names: Austedo, Austedo Xr, Austedo Xr Titration Kt(Wk1-4)
At a glance
- Medicare prescriptions, 2024
- 176,022
- Medicare drug cost
- $1.19B
- Average cost per prescription
- $6,759
- Clinicians who prescribed it
- 6,649
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
AUSTEDO XR ® and AUSTEDO ® are indicated in adults for the treatment of: chorea associated with Huntington’s disease tardive dyskinesia AUSTEDO XR and
From the FDA-approved prescribing information (label dated February 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: DEPRESSION AND SUICIDALITY IN PATIENTS WITH HUNTINGTON’S DISEASE AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of AUSTEDO XR or AUSTEDO must balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington’s disease. AUSTEDO XR and AUSTEDO are…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatric Nurse Practitioners 26.2%
- Psychiatry 24.0%
- Neurology 17.3%
- Nurse Practitioners 11.8%
- Family Medicine 5.9%
- Internal Medicine 5.7%
- Physician Assistants 5.1%
- Geriatric Medicine 1.1%
- Child & Adolescent Psychiatry 0.7%
- General Practice 0.4%
- Hospitalist 0.3%
- Child Neurology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 284% from 2019 to 2024.
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Teva Neuroscience, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 6 mg | purple round tablet, 10 mm | SD 6 |
| 6 mg | gray round tablet, 9 mm | Q6 |
| 9 mg | blue round tablet, 10 mm | SD 9 |
| 12 mg | brown round tablet, 10 mm | SD 12 |
| 12 mg | blue round tablet, 9 mm | Q12 |
| 18 mg | gray round tablet, 9 mm | Q18 |
| 24 mg | purple round tablet, 9 mm | Q24 |
| 30 mg | orange round tablet, 9 mm | Q30 |
| 36 mg | purple round tablet, 9 mm | Q36 |
| 42 mg | orange round tablet, 9 mm | Q42 |
| 48 mg | pink round tablet, 9 mm | Q48 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $8.2M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Teva Pharmaceuticals USA, Inc. $8.2M
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.